Elekta (OTCMKTS:EKTAY) Shares Gap Up - Time to Buy?

Elekta AB (OTCMKTS:EKTAY - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $4.88, but opened at $5.24. Elekta shares last traded at $5.13, with a volume of 684 shares.

Analyst Upgrades and Downgrades

Separately, Danske cut Elekta to a "hold" rating in a research note on Tuesday, June 3rd.

Elekta Trading Up 5.0%

The company has a market cap of $1.97 billion, a P/E ratio of 102.52 and a beta of 1.22. The company has a quick ratio of 0.86, a current ratio of 1.09 and a debt-to-equity ratio of 0.70. The firm's 50-day moving average price is $5.10 and its 200-day moving average price is $5.39.

Elekta (OTCMKTS:EKTAY - Get Free Report) last released its quarterly earnings data on Wednesday, May 28th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.02). Elekta had a return on equity of 11.55% and a net margin of 1.15%. The business had revenue of $503.22 million during the quarter, compared to the consensus estimate of $507.19 million. As a group, equities research analysts expect that Elekta AB will post 0.36 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.